Hualan Biological Engineering Inc
SZSE:002007
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.84
22.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hualan Biological Engineering Inc
Hualan Biological Engineering Inc
Net Issuance of Debt
Hualan Biological Engineering Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hualan Biological Engineering Inc
SZSE:002007
|
Net Issuance of Debt
¥150m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Beigene Ltd
HKEX:6160
|
Net Issuance of Debt
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Issuance of Debt
-¥164.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Issuance of Debt
¥38m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Issuance of Debt
¥358.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hualan Biological Engineering Inc
Glance View
Hualan Biological Engineering Inc., nestled in the heart of China, operates at the crossroads of innovation and health, focusing primarily on the production of vaccines and blood products. The company is at the forefront of a critical industry, ensuring the creation of products that play a pivotal role in maintaining public health. With a dedicated pursuit of scientific excellence, Hualan develops vaccines that protect against contagious diseases and specializes in plasma-derived therapeutics that have become a backbone in treating a variety of conditions requiring immune support or clotting factors. This dual focus not only showcases their expertise but also broadens their commercial portfolio, tapping into markets where demand is continually rising. Revenue streams for Hualan Biological are primarily driven by their deep penetration into domestic markets, where there is a growing emphasis on healthcare innovation and quality assurance. The company capitalizes on its research and development capabilities, which have enabled it to secure a strong pipeline of products and stay ahead in a competitive landscape. By leveraging its robust distribution network and quality manufacturing processes, Hualan ensures that its products reach hospitals and health institutions rapidly. This strategic orchestration of science and logistics allows Hualan not only to generate substantial revenues but also to reinforce its reputation as a leader within China's biopharmaceutical sector, ensuring it remains a vital contributor to public health initiatives.
See Also
What is Hualan Biological Engineering Inc's Net Issuance of Debt?
Net Issuance of Debt
150m
CNY
Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Net Issuance of Debt amounts to 150m CNY.
What is Hualan Biological Engineering Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
14%
Over the last year, the Net Issuance of Debt growth was -51%. The average annual Net Issuance of Debt growth rates for Hualan Biological Engineering Inc have been -39% over the past three years , and 14% over the past ten years .
You don't have any saved screeners yet
